Skip to main content

Politicians make promises on their stump — we watch and hold them accountable.

Help keep the record honest →Create an account
Bills/119th Congress · House

H.R. 8857

Introduced

Next GEN Act of 2026

Sponsor
DJoseph D. Morelle· New York
Introduced
May 15, 2026
Policy area
Health
Latest action
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.May 15, 2026

Plain-language analysis

Not yet analyzed.

A plain-language breakdown — including any hidden or off-intent provisions and whether the bill was fast-tracked — is generated separately and reviewed before publishing. It will appear here once ready. Until then, the verbatim text below and the official source are the record.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8857 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8857 To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES May 15, 2026 Mr. Morelle (for himself, Mr. Gottheimer, Mr. Pfluger, and Mr. Kean) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Next Generation Medicines Act of 2026'' or the ``Next GEN Act of 2026''. SEC. 2. ADJUSTING RULES FOR ENGINEERED CYCLIC PEPTIDES UNDER DRUG PRICE NEGOTIATION PROGRAM. (a) In General.--Section 1192(e) of the Social Security Act (42 U.S.C. 1320f-1(e)) is amended-- (1) in paragraph (1)(A)(ii), by inserting ``(or, in the case of an engineered cyclic peptide (as defined in paragraph (5)), 11 years)'' after ``7 years''; and (2) by adding at the end the following new paragraph: ``(5) Engineered cyclic peptide defined.--In this subsection, the term `engineered cyclic peptide' means a polymer that-- ``(A) is composed principally of amino acids; ``(B) contains not less than 1 cyclic structure produced through head-to-tail cyclization, head-to- side-chain cyclization, side-chain-to-tail cyclization, or side-chain-to-side-chain cyclization; ``(C) contains not more than 40 amino acids; ``(D) was identified for development using a genetically encoded library screening method; ``(E) is not naturally derived; and ``(F) is orally administered, inhaled, or otherwise self-administered.''. (b) Effective Date.--The amendments made by this section shall apply with respect to lists published under section 1192(a) of the Social Security Act (42 U.S.C. 1320f-1(a)) on or after the date of the enactment of this section. <all>

StumpWatch is live, and the record is still growing. Many promises and positions aren’t tracked yet, and some features are still in beta. Add a sourced promise and help keep the record honest.

Help keep the record honest →